Trial · NCT02508194
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Had a First Episode of Acute Respiratory Syncytial Virus-Associated Respiratory Illness (ARA-RI) During Respiratory Syncytial Virus (RSV) Surveillance Period in Season 1 | Placebo + IIV | 1.6 | Percentage of Participants | ||
| Percentage of Participants Who Had a First Episode of Acute Respiratory Syncytial Virus-Associated Respiratory Illness (ARA-RI) During Respiratory Syncytial Virus (RSV) Surveillance Period in Season 1 | MEDI7510 + IIV | 1.7 | Percentage of Participants | ||
| Percentage of Participants Who Had a RSV Polymerase Chain Reaction (PCR)-Positive Respiratory Illness During the RSV Surveillance Period in Season 1 | Placebo + IIV | 1.6 | Percentage of Participants | ||
| Percentage of Participants Who Had a RSV Polymerase Chain Reaction (PCR)-Positive Respiratory Illness During the RSV Surveillance Period in Season 1 | MEDI7510 + IIV | 1.7 | Percentage of Participants | ||
| Geometric Mean Responses (GMRs) of Serum Antibodies Concentration Against RSV by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay | Placebo + IIV | Day 1 | 83.39 | 95% Confidence Interval 78.91 to 88.12 | Fragment antigen-binding (F AB) unit/mL |
| Geometric Mean Responses (GMRs) of Serum Antibodies Concentration Against RSV by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay | MEDI7510 + IIV | Day 1 | 77.96 | 95% Confidence Interval 73.66 to 82.50 | Fragment antigen-binding (F AB) unit/mL |
| Geometric Mean Responses (GMRs) of Serum Antibodies Concentration Against RSV by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay | Placebo + IIV | Day 29 | 80.05 | 95% Confidence Interval 75.68 to 84.68 | Fragment antigen-binding (F AB) unit/mL |
| Geometric Mean Responses (GMRs) of Serum Antibodies Concentration Against RSV by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay | MEDI7510 + IIV | Day 29 | 999.03 | 95% Confidence Interval 944.40 to 1056.81 | Fragment antigen-binding (F AB) unit/mL |
| Geometric Mean Responses (GMRs) of Serum Antibodies Concentration Against RSV by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay | Placebo + IIV | End of Season 1 | 79.95 | 95% Confidence Interval 75.27 to 84.93 | Fragment antigen-binding (F AB) unit/mL |
| Geometric Mean Responses (GMRs) of Serum Antibodies Concentration Against RSV by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay | MEDI7510 + IIV | End of Season 1 | 370.88 | 95% Confidence Interval 350.90 to 391.99 | Fragment antigen-binding (F AB) unit/mL |
| Geometric Mean Fold Change of Serum Antibodies Concentration Against RSV by Anti-F IgG Assay | Placebo + IIV | Day 29 | 0.96 | 95% Confidence Interval 0.94 to 0.98 | Fold Change |
| Geometric Mean Fold Change of Serum Antibodies Concentration Against RSV by Anti-F IgG Assay | MEDI7510 + IIV | Day 29 | 12.78 | 95% Confidence Interval 11.96 to 13.65 | Fold Change |
| Geometric Mean Fold Change of Serum Antibodies Concentration Against RSV by Anti-F IgG Assay | Placebo + IIV | End of Season 1 | 0.94 | 95% Confidence Interval 0.91 to 0.96 | Fold Change |
| Geometric Mean Fold Change of Serum Antibodies Concentration Against RSV by Anti-F IgG Assay | MEDI7510 + IIV | End of Season 1 | 4.60 | 95% Confidence Interval 4.34 to 4.88 | Fold Change |
| Percentage of Participants Who Had a Post-dose Seroresponse to RSV as Measured by Anti-F IgG Assay | Placebo + IIV | Day 29 | 0.8 | 95% Confidence Interval 0.3 to 1.5 | Percentage of Participants |
| Percentage of Participants Who Had a Post-dose Seroresponse to RSV as Measured by Anti-F IgG Assay | MEDI7510 + IIV | Day 29 | 92.9 | 95% Confidence Interval 91 to 94.4 | Percentage of Participants |
| Percentage of Participants Who Had a Post-dose Seroresponse to RSV as Measured by Anti-F IgG Assay | Placebo + IIV | End of Season 1 | 1.6 | 95% Confidence Interval 0.9 to 2.7 | Percentage of Participants |
| Percentage of Participants Who Had a Post-dose Seroresponse to RSV as Measured by Anti-F IgG Assay | MEDI7510 + IIV | End of Season 1 | 65.8 | 95% Confidence Interval 62.5 to 69 | Percentage of Participants |
| Geometric Mean Titers (GMTs) of Strain-Specific Hemagglutination Inhibition (HAI) Antibodies to Influenza Antigens Contained in the Seasonal Influenza Vaccine | Placebo + IIV | H1N1, Day 1 | 54.26 | 95% Confidence Interval 48.610 to 60.565 | Titer |
| Geometric Mean Titers (GMTs) of Strain-Specific Hemagglutination Inhibition (HAI) Antibodies to Influenza Antigens Contained in the Seasonal Influenza Vaccine | MEDI7510 + IIV | H1N1, Day 1 | 55.77 | 95% Confidence Interval 50.066 to 62.115 | Titer |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02508194/results